Aurinia Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aurinia Pharmaceuticals Inc. on July 16, 2021. The registrant is incorporated in Canada and maintains principal executive offices in Victoria, British Columbia. The report addresses a specific corporate governance event regarding the listing status of the company's common shares.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the voluntary delisting of the Company's common shares from the Toronto Stock Exchange (TSX). This delisting is effective as of the close of trading on July 30, 2021. Following this date, the shares will no longer trade on the TSX but will continue to trade on the NASDAQ Capital Market under the symbol AUPH.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the operational change of delisting. The Company explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and undertakes no duty to update or revise the information except as required by law.
Key Facts for Investor Verification
- Delisting Date: Confirm the effective date of TSX delisting is July 30, 2021.
- Trading Venue: Verify that trading continues exclusively on the NASDAQ Capital Market under symbol AUPH.
- Press Release: Review Exhibit 99.1 for the full text of the press release announcing the delisting.
- Financial Data: Note that this 8-K contains no financial performance data; refer to recent 10-Q or 10-K filings for financial metrics.